

WEBMD HEALTH CORP.

FORM 8-K (Current report filing)

Filed 05/02/17 for the Period Ending 05/02/17

Address	395 HUDSON STREET NEW YORK, NY 10014
Telephone	212-624-3700
CIK	0001326583
Symbol	WBMD
SIC Code	7389 - Business Services, Not Elsewhere Classified
Industry	Internet Services
Sector	Technology
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

**May 2, 2017
Date of Report (Date of earliest event reported)**

WEBMD HEALTH CORP.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-35337
(Commission
File Number)

20-2783228
(I.R.S. Employer
Identification No.)

395 Hudson Street
New York, New York 10014
(Address of principal executive offices, including zip code)

(212) 624-3700
(Registrant's telephone number, including area code)

(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On May 2, 2017, WebMD Health Corp. issued a press release announcing its results for the quarter ended March 31, 2017. A copy of the press release is attached as Exhibit 99.1 to this Current Report. Exhibit 99.2 to this Current Report contains the financial tables that accompanied the press release. Exhibit 99.3 to this Current Report includes forward-looking financial information that accompanied the press release. Exhibit 99.4 to this Current Report contains an Annex to the press release entitled “Explanation of Non-GAAP Financial Measures.”

Exhibits 99.1 through 99.4 are being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall any of those exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are furnished herewith:

<i>Exhibit Number</i>	<i>Description</i>
99.1	Press Release, dated May 2, 2017, regarding the Registrant’s results for the quarter ended March 31, 2017
99.2	Financial Tables accompanying Exhibit 99.1
99.3	Financial Guidance Summary accompanying Exhibit 99.1
99.4	Annex A to Exhibits 99.1 through 99.3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

WEBMD HEALTH CORP.

By: /s/ Lewis H. Leicher

Lewis H. Leicher
Senior Vice President

Dated: May 2, 2017

EXHIBIT INDEX

<i>Exhibit Number</i>	<i>Description</i>
99.1	Press Release, dated May 2, 2017, regarding the Registrant's results for the quarter ended March 31, 2017
99.2	Financial Tables accompanying Exhibit 99.1
99.3	Financial Guidance Summary accompanying Exhibit 99.1
99.4	Annex A to Exhibits 99.1 through 99.3



Contacts:

Investors:

Mary Anne Lerma
mlerma@webmd.net
212-624-3817

Media:

Adam Grossberg
agrossberg@webmd.net
212-624-3790

WebMD Reports First Quarter Financial Results and Reaffirms 2017 Guidance

New York, NY (May 2, 2017) - WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced financial results for the three months ended March 31, 2017.

“As expected, our first quarter results were below last year’s reflecting a more challenging macro environment for many of our biopharma customers and disappointing sales in 2016 in our Health Services business,” said Dr. Steven Zatz, CEO of WebMD. “We remain focused on restoring WebMD’s growth by providing the highest-quality health content, guidance and tools for both consumers and healthcare professionals, as well as delivering superior results for our advertisers and value for our shareholders.”

Financial Highlights

For the three months ended March 31, 2017:

- Revenue was \$154.1 million, compared to \$158.6 million in the prior year period, a decrease of 3%. Advertising and sponsorship revenue was \$121.5 million, compared to \$122.4 million in the prior year period. Health services revenue was \$24.5 million, compared to \$28.3 million in the prior year period. Information services revenue was \$8.0 million, compared to \$7.9 million in the prior year period.
- Net income was \$12.3 million or \$0.30 per diluted share, compared to \$15.7 million or \$0.36 per diluted share in the prior year period.
- Earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”) was \$41.0 million, or 26.6% of revenue, compared to \$47.1 million, or 29.7% of revenue, in the prior year period.

Balance Sheet Highlights

As of March 31, 2017, WebMD had: approximately \$1.034 billion in cash and investments; \$1.06 billion in aggregate principal amount of convertible notes outstanding; and approximately 37.8 million shares of its common stock outstanding (including approximately 700 thousand unvested shares of restricted stock).

During the first quarter, WebMD did not repurchase any shares of its common stock under its stock repurchase program. As of March 31, 2017, approximately \$45.6 million remained available for repurchases under WebMD’s stock repurchase program. Under its stock repurchase program,

WebMD may repurchase shares from time to time in the open market, through block trades or in private transactions, depending on market conditions and other factors.

Financial Guidance

Today, WebMD reaffirmed its guidance for 2017 that was previously provided on February 16, 2017.

For the full year ending December 31, 2017, WebMD continues to expect:

- Revenue to be approximately \$710 million to \$730 million, an increase of 1% to 4% from the prior year.
 - \$580 million to \$598 million of revenue is expected to be from advertising and sponsorship, an increase of 3% to 7% from the prior year. Advertising and sponsorship from biopharma customers is expected to grow 2% to 5%. Advertising and sponsorship from OTC, CPG and other customers is expected to grow 8% to 11%.
 - \$99 million to \$100 million of revenue is expected to be from health services, compared to \$113.9 million in 2016.
 - \$31 million to \$32 million of revenue is expected to be from information services, compared to \$29.8 million in 2016.
- Net income to be approximately \$89.0 million to \$98.0 million, or \$1.97 to \$2.10 per diluted share, compared to \$91.3 million, or \$1.97 per diluted share, in 2016.
- Adjusted EBITDA to be approximately \$233 million to \$243 million, an increase of 1% to 5% from the prior year. Adjusted EBITDA, as a percentage of revenue, to be approximately 32.8% to 33.3%, compared to 32.7% in the prior year.

Dr. Zatz continued, “Our first quarter results were at the high end of our financial guidance provided in February and we are reaffirming our 2017 guidance today. We have considered the near term pressures facing many of our biopharma customers in our financial guidance; however, we believe a strong drug pipeline, the continued shift toward digital advertising and the increased consumerization of healthcare present longer-term growth opportunities for WebMD across all areas of our business.”

For the second quarter of 2017, WebMD expects:

- Revenue to be approximately \$170 million to \$173 million, an increase of approximately 1% to 3% from the prior year period.
- Net income to be approximately \$16.9 million to \$18.5 million, a decrease of approximately 5% to an increase of approximately 4% from the prior year period.
- Adjusted EBITDA to be approximately \$49 million to \$51 million, a decrease of approximately 2% to an increase of approximately 2% from the prior year period.

A schedule summarizing the Company’s financial guidance is attached to this press release.

Analyst and Investor Conference Call

WebMD will hold a conference call with investors and analysts at 4:45 p.m. (Eastern) today. The call can be accessed at www.wbmd.com (in the Investor Relations section). A replay of the audio webcast will be available at the same web address.

About WebMD

WebMD Health Corp. (NASDAQ: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers, and health plans through our public and private online portals, mobile platforms and health-focused publications.

The WebMD Health Network includes WebMD.com, Medscape.com, MedicineNet.com, eMedicineHealth.com, RxList.com, OnHealth.com, [Medscape Education \(Medscape.org\)](http://Medscape Education (Medscape.org)) and other WebMD owned sites and apps.

All statements contained in this press release and the related analyst and investor conference call, other than statements of historical fact, are forward-looking statements, including those regarding: explorations of possible transactions and other strategic alternatives; guidance on our future financial results and other projections or measures of our future performance; market opportunities or momentum and our ability to capitalize on them; and the benefits expected from new or expected contracts with customers, from new or updated products or services and from other potential sources of additional revenue. These statements speak only as of the date of this press release, are based on our current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: the nature and timing of any possible transaction or other strategic alternative or of any potential benefits from any such transaction or other alternative; market acceptance of our products and services; our relationships with customers and other factors affecting their use of our services and the timing of entry into and implementation of specific contracts with customers, including regulatory matters affecting their products and services; our ability to deploy new or updated services and to create new or enhanced revenue streams from those services; our ability to attract and retain qualified personnel; and changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet and information technology industries. Further information about these matters can be found in our Securities and Exchange Commission filings and this press release is intended to be read in conjunction with information contained in those filings. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

This press release, and the accompanying tables, include both financial measures in accordance with accounting principles generally accepted in the United States of America, or GAAP, as well as certain non-GAAP financial measures. The tables attached to this press release include reconciliations of these non-GAAP financial measures to GAAP financial measures. In addition, an "Explanation of Non-GAAP Financial Measures" is attached to this press release as Annex A.

WebMD[®], Medscape[®], CME Circle[®], Medpulse[®], eMedicine[®], MedicineNet[®], theheart.org[®] and RxList[®] are among the trademarks of WebMD Health Corp. or its subsidiaries.

WEBMD HEALTH CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data, unaudited)

	Three Months Ended March 31,	
	2017	2016
Revenue	\$ 154,058	\$ 158,553
Cost of operations	63,501	62,513
Sales and marketing	36,008	33,756
General and administrative	22,619	23,756
Depreciation and amortization	7,061	7,487
Interest income	1,953	206
Interest expense	7,066	5,100
Other expense	262	—
Income before income tax provision	19,494	26,147
Income tax provision	7,161	10,429
Net income	<u>\$ 12,333</u>	<u>\$ 15,718</u>
Net income per common share:		
Basic	<u>\$ 0.33</u>	<u>\$ 0.42</u>
Diluted	<u>\$ 0.30</u>	<u>\$ 0.36</u>
Weighted-average shares outstanding used in computing income per common share:		
Basic	<u>36,866</u>	<u>37,267</u>
Diluted	<u>49,828</u>	<u>52,335</u>

WEBMD HEALTH CORP.
CONSOLIDATED SUPPLEMENTAL FINANCIAL INFORMATION
(In thousands, unaudited)

	Three Months Ended	
	March 31,	
	<u>2017</u>	<u>2016</u>
Revenue		
Advertising and sponsorship		
Biopharma and medical device	\$ 89,480	\$ 88,685
OTC, CPG and other	31,998	33,754
	<u>121,478</u>	<u>122,439</u>
Health services	24,539	28,255
Information services	8,041	7,859
	<u>\$ 154,058</u>	<u>\$ 158,553</u>
Net income	<u>\$ 12,333</u>	<u>\$ 15,718</u>
Interest, taxes, non-cash and other items (a)		
Interest income	(1,953)	(206)
Interest expense	7,066	5,100
Income tax provision	7,161	10,429
Depreciation and amortization	7,061	7,487
Non-cash stock-based compensation	9,023	8,528
Other expense	262	—
Earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”) (b)	<u>\$ 40,953</u>	<u>\$ 47,056</u>

- (a) Reconciliation of net income to Adjusted EBITDA.
(b) See Annex A-Explanation of Non-GAAP Financial Measures.

WEBMD HEALTH CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)

	March 31, 2017 <u>(unaudited)</u>	December 31, 2016 <u> </u>
<u>Assets</u>		
Cash and cash equivalents	\$ 88,567	\$ 492,424
Accounts receivable, net	158,228	179,454
Investments	945,885	498,500
Prepaid expenses and other current assets	21,381	15,294
Total current assets	<u>1,214,061</u>	<u>1,185,672</u>
Property and equipment, net	81,870	83,296
Goodwill	202,980	202,980
Intangible assets, net	7,124	7,774
Deferred tax assets, net	212,690	14,544
Other assets	7,382	6,920
Total Assets	<u>\$1,726,107</u>	<u>\$ 1,501,186</u>
<u>Liabilities and Stockholders' Equity</u>		
Accrued expenses	\$ 56,082	\$ 78,597
Deferred revenue	123,411	105,310
2.50% convertible notes due 2018, net	<u>398,512</u>	<u>—</u>
Total current liabilities	578,005	183,907
2.50% convertible notes due 2018, net	—	398,066
1.50% convertible notes due 2020, net	295,724	295,432
2.625% convertible notes due 2023, net	351,531	351,190
Other long-term liabilities	28,067	28,731
Stockholders' equity	472,780	243,860
Total Liabilities and Stockholders' Equity	<u>\$1,726,107</u>	<u>\$ 1,501,186</u>

WEBMD HEALTH CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)

	Three Months Ended	
	March 31,	
	2017	2016
Cash flows from operating activities:		
Net income	\$ 12,333	\$ 15,718
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	7,061	7,487
Non-cash interest, net	1,079	897
Non-cash stock-based compensation	9,023	8,528
Deferred income taxes	6,621	9,074
Changes in operating assets and liabilities:		
Accounts receivable	21,226	(3,070)
Prepaid expenses and other, net	(7,850)	1,731
Accrued expenses and other long-term liabilities	(22,722)	(20,147)
Deferred revenue	18,101	13,598
Net cash provided by operating activities	<u>44,872</u>	<u>33,816</u>
Cash flows from investing activities:		
Purchases of property and equipment	(5,427)	(9,229)
Purchases of investments	(446,042)	—
Partial redemption of cost-method investment	—	526
Net cash used in investing activities	<u>(451,469)</u>	<u>(8,703)</u>
Cash flows from financing activities:		
Proceeds from exercise of stock options	6,604	30,165
Cash used for withholding taxes due on stock-based awards	(3,864)	(890)
Maturity of convertible notes	—	(102,682)
Net cash provided by (used in) financing activities	<u>2,740</u>	<u>(73,407)</u>
Net decrease in cash and cash equivalents	(403,857)	(48,294)
Cash and cash equivalents at beginning of period	492,424	641,165
Cash and cash equivalents at end of period	<u>\$ 88,567</u>	<u>\$ 592,871</u>

WEBMD HEALTH CORP.
NET INCOME PER COMMON SHARE
(In thousands, except per share data, unaudited)

	Three Months Ended March 31,	
	2017	2016
Numerator:		
Net income – Basic	\$12,333	\$15,718
Interest expense on 1.50% convertible notes, net of tax	878	878
Interest expense on 2.50% convertible notes, net of tax	1,827	1,827
Interest expense on 2.25% convertible notes, net of tax	—	457
Net income – Diluted	<u>\$15,038</u>	<u>\$18,880</u>
Denominator:		
Weighted-average shares – Basic	36,866	37,267
Stock options and restricted stock	1,007	1,755
1.50% convertible notes	5,721	5,694
2.50% convertible notes	6,234	6,205
2.25% convertible notes	—	1,414
Adjusted weighted-average shares after assumed conversions – Diluted	<u>49,828</u>	<u>52,335</u>
Net income per common share:		
Basic	<u>\$ 0.33</u>	<u>\$ 0.42</u>
Diluted	<u>\$ 0.30</u>	<u>\$ 0.36</u>

WEBMD HEALTH CORP.
FINANCIAL GUIDANCE FOR THE YEAR ENDING DECEMBER 31, 2017
(In millions, except per share amounts)

	Guidance Range	
Revenue		
Advertising and sponsorship		
Biopharma and medical device	\$437.0	\$450.0
OTC, CPG and other	143.0	148.0
	<u>580.0</u>	<u>598.0</u>
Health services	99.0	100.0
Information services	31.0	32.0
	<u>\$710.0</u>	<u>\$730.0</u>
Net income	<u>\$ 89.0</u>	<u>\$ 98.0</u>
Interest, taxes, non-cash and other items (a)		
Interest expense, net	21.0	21.0
Income tax provision (d)	53.7	59.7
Depreciation and amortization	32.0	30.0
Non-cash stock-based compensation	37.0	34.0
Other expense	0.3	0.3
	<u>\$233.0</u>	<u>\$243.0</u>
Earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”) (b)	<u>\$233.0</u>	<u>\$243.0</u>
Income per share:		
Basic	<u>\$ 2.41</u>	<u>\$ 2.61</u>
Diluted (c)	<u>\$ 1.97</u>	<u>\$ 2.10</u>
Calculation of income per share:		
Net income (numerator for basic income per share)	\$ 89.0	\$ 98.0
Add-back of interest expense, net of tax, related to:		
1.50% convertible notes	3.5	3.5
2.50% convertible notes	7.3	7.3
2.625% convertible notes	6.7	6.7
Numerator for diluted income per share	<u>\$106.5</u>	<u>\$115.5</u>
Weighted average shares outstanding (denominator for basic income per share)	37.0	37.5
Stock options and restricted stock	1.0	1.5
Weighted average shares issuable upon conversion of:		
1.50% convertible notes	5.7	5.7
2.50% convertible notes	6.2	6.2
2.625% convertible notes	4.2	4.2
Denominator for diluted income per share	<u>54.1</u>	<u>55.1</u>

- (a) Reconciliation of net income to Adjusted EBITDA.
- (b) See Annex A—Explanation of Non-GAAP Financial Measures.
- (c) See Supplemental 2017 Guidance for Income Per Share Calculation below.
- (d) The income tax provision included in the 2017 financial guidance excludes any adjustments for excess tax benefits, except for actual activity for the year-to-date period ended March 31, 2017, because such adjustments will be based on actual exercise or settlement activity of stock-based awards in future periods, which cannot be estimated at this time.

Additional information regarding forecast for the quarter ending June 30, 2017:

- Revenue is forecasted to be between \$170 million to \$173 million.
- Revenue distribution is forecasted to be: approximately 62.5% from Advertising and sponsorship—Biopharma and medical device; 19% from Advertising and sponsorship—OTC, CPG and other; 14% from Health services; and 4.5% from Information services.
- Net income is forecasted to be between \$16.9 million to \$18.5 million.
- Adjusted EBITDA is forecasted to be between \$49 million to \$51 million.
- In calculating Adjusted EBITDA, the Company excluded the following expense items that are included in the calculation of Net Income: interest expense, net of \$5.2 million; depreciation and amortization of \$7.6 to \$7.4 million; non-cash stock-based compensation of \$9.0 to \$8.6 million; and income tax provision of \$10.3 to \$11.3 million. See Annex A—Explanation of Non-GAAP Financial Measures.

The above guidance does not include the impact if any, of future deployment of capital for items such as share repurchases, convertible note repurchases or acquisitions, gains or losses from discontinued operations, other non-recurring, one-time or unusual items or the impact, if any, of the Board of Directors’ review of potential strategic alternatives.

WEBMD HEALTH CORP.
SUPPLEMENTAL 2017 GUIDANCE FOR INCOME PER SHARE CALCULATION

Based on the Company's Financial Guidance for the Year Ending December 31, 2017, the 1.50% convertible notes, the 2.50% convertible notes and the 2.625% convertible notes are expected to be dilutive to net income on both the low end and high end of the full year guidance range. Additionally, the 1.50% convertible notes, the 2.50% convertible notes and the 2.625% convertible notes may be dilutive in certain future quarters, depending on the amount of net income for such quarter. The following table contains the approximate level of net income for an individual future quarter and for the full year 2017 at which each of the series of convertible notes would become dilutive to income per share. To the extent this net income is exceeded for any such period, the table also includes the amounts by which the numerator and denominator should each be adjusted for purposes of the diluted income per share calculation.

	Quarterly Amounts			Annual Amounts		
	1.50% Convertible Notes	2.50% Convertible Notes	2.625% Convertible Notes	1.50% Convertible Notes	2.50% Convertible Notes	2.625% Convertible Notes
<i>All amounts in millions</i>						
Approximate net income at which convertible notes become dilutive (a)	\$ 5.8	\$ 11.9	\$ 17.5	\$ 23.3	\$ 47.7	\$ 69.8
Interest expense, net of tax to add-back to net income (numerator)	\$ 0.9	\$ 1.8	\$ 1.7	\$ 3.5	\$ 7.3	\$ 6.7
Additional shares to include in weighted-average diluted share count (denominator)	5.7	6.2	4.2	5.7	6.2	4.2

(a) These net income amounts assume a weighted-average diluted share count of 38.0 million shares attributable to common shares, stock options and restricted stock (prior to the effect of convertible notes) and are subject to change as such weighted-average share count changes for a given quarter or annual period.

ANNEX A

Explanation of Non-GAAP Financial Measures

The accompanying WebMD Health Corp. press release and attachments include both financial measures in accordance with U.S. generally accepted accounting principles, or GAAP, as well as non-GAAP financial measures. The non-GAAP financial measures represent earnings before interest, taxes, non-cash and other items (which we refer to as “Adjusted EBITDA”). Adjusted EBITDA should be viewed as supplemental to, and not as an alternative for net income or loss calculated in accordance with GAAP (referred to below as “net income”). The attachments to the press release include reconciliations of non-GAAP financial measures to GAAP financial measures.

Adjusted EBITDA is used by our management as an additional measure of our company’s performance for purposes of business decision-making, including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our company’s financial results that may not be shown solely by period-to-period comparisons of net income. In addition, we may use Adjusted EBITDA in the incentive compensation programs applicable to some of our employees in order to evaluate our company’s performance. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature. In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in net income, as well as trends in those items. The amounts of those items are set forth, for the applicable periods, in the reconciliations of net income to Adjusted EBITDA that accompany our press releases and disclosure documents containing non-GAAP financial measures, including the reconciliations contained in the accompanying press release attachments.

We believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results for reasons similar to the reasons why our management finds it useful and because it helps facilitate investor understanding of decisions made by management in light of the performance metrics used in making those decisions. In addition, as more fully described below, we believe that providing Adjusted EBITDA, together with a reconciliation of net income to Adjusted EBITDA, helps investors make comparisons between our company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation. However, Adjusted EBITDA is intended to provide a supplemental way of comparing our company with other public companies and is not intended as a substitute for comparisons based on net income. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.

The following is an explanation of the items excluded by us from Adjusted EBITDA but included in net income:

- **Depreciation and Amortization** . Depreciation and amortization expense is a non-cash expense relating to capital expenditures and intangible assets arising from acquisitions that are expensed on a straight-line basis over the estimated useful life of the related assets. We exclude depreciation and amortization expense from Adjusted EBITDA because we believe that (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired tangible and intangible assets. Accordingly, we believe that this exclusion assists management and investors in making period-to-period comparisons of operating performance. Investors should note that the use of tangible and intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation and should also note that such expense will recur in future periods.

- Stock-Based Compensation Expense** . Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards to employees. We believe that excluding the effect of stock-based compensation from Adjusted EBITDA assists management and investors in making period-to-period comparisons in our company's operating performance because (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants in connection with acquisitions. Additionally, we believe that excluding stock-based compensation from Adjusted EBITDA assists management and investors in making meaningful comparisons between our company's operating performance and the operating performance of other companies that may use different forms of employee compensation or different valuation methodologies for their stock-based compensation. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future. Stock-based compensation expenses included in the Consolidated Statement of Operations are summarized as follows:

	Three Months Ended	
	March 31,	
	2017	2016
Non-cash stock-based compensation included in:		
Cost of operations	\$ 1,576	\$ 1,290
Sales and marketing	\$ 1,777	\$ 1,562
General and administrative	\$ 5,670	\$ 5,676

- Interest Income and Expense**. Interest income is associated with the level of marketable debt securities and other interest bearing accounts in which we invest, and interest expense is related to our company's capital structure (including non-cash interest expense relating to our convertible notes). Interest income and expense varies over time due to a variety of financing transactions and due to acquisitions and divestitures that we have entered into or may enter into in the future. We have, in the past, issued convertible debentures, repurchased shares in cash tender offers and repurchased shares and convertible debentures through other repurchase transactions, and completed the divestiture of certain businesses. We exclude interest income and interest expense from Adjusted EBITDA (i) because these items are not directly attributable to the performance of our business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different capital structures. Investors should note that interest income and expense will recur in future periods. The following provides detail regarding the components of interest expense of our convertible notes:

	Three Months Ended	
	March 31,	
	2017	2016
Non-cash interest expense		
2.25% Convertible Notes	\$ —	\$ 159
2.50% Convertible Notes	\$ 446	\$ 446
1.50% Convertible Notes	\$ 292	\$ 292
2.625% Convertible Notes	\$ 341	\$ —
Cash interest expense		
2.25% Convertible Notes	\$ —	\$ 577
2.50% Convertible Notes	\$ 2,500	\$ 2,500
1.50% Convertible Notes	\$ 1,125	\$ 1,125
2.625% Convertible Notes	\$ 2,362	\$ —

-
- **Income Tax Provision (Benefit).** We maintain a valuation allowance on a portion of our net deferred tax assets, the amount of which may change from quarter to quarter through adjustments to the income tax provision (benefit). The income tax provision (benefit) is also adjusted each quarter for excess tax benefits and/or deficiencies related to stock-based awards that vest or are settled in such quarter. The timing of such adjustments has not been consistent and as a result, our income tax expense can fluctuate significantly from period to period in a manner not directly related to our operating performance. We exclude the income tax provision (benefit) from Adjusted EBITDA (i) because we believe that the income tax provision (benefit) is not directly attributable to the underlying performance of our business operations and, accordingly, its exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different tax attributes. Investors should note that income tax provision (benefit) will recur in future periods.
 - **Other Items.** We engage in other activities and transactions that can impact our net income. In recent periods, these other items included, but were not limited to: (i) gain on investments; (ii) loss on repurchases of our convertible notes; (iii) severance expense; and (iv) legal fees and other expenses incurred in connection with the process conducted by our Board of Directors to explore strategic alternatives for our company. We exclude these other items from Adjusted EBITDA because we believe these activities or transactions are not directly attributable to the performance of our business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance. Investors should note that some of these other items may recur in future periods.